New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export PBM’s income statement to Excel — free account
Psyence Biomedical Ltd.
PBM
2.97
0.11
+3.85%
After hours trading: 3.01, up 1.35%, last trade Fri 4:09pm Eastern.
Follow PBM
Alert me
An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.
| Mar '26 | Mar '25 | Mar '24 | Dec '23 | Jan '22 | Jan '21 | |
|---|---|---|---|---|---|---|
R&D Expenses |
1.47 | 0.34 | 0.95 | 0.96 | — | — |
SG&A Expenses |
1.11 | 1.69 | 0.64 | 1.80 | 1.29 | 0.33 |
Operating Income |
(6.24) | (3.66) | (2.75) | (2.75) | — | — |
Non-operating Income/Expense |
(0.70) | 4.67 | (48.41) | (48.41) | (5.76) | (8.56) |
Non-operating Interest Expenses |
0.01 | 0.01 | 0.05 | 0.05 | 3.55 | 0.00 |
Investment Gain/Loss (Other) |
— | — | — | 0.00 | — | — |
Income (Other) |
— | — | — | 0.00 | — | — |
| (6.94) | 1.01 | (51.16) | (51.16) | 8.01 | 8.23 | |
Income Tax Provision |
— | — | — | 0.00 | — | — |
Income after Tax |
(6.94) | 1.01 | (51.16) | (51.16) | — | — |
Minority Interest |
— | — | — | 0.00 | — | — |
Net Income Common |
(6.94) | 1.01 | (51.16) | (51.16) | 8.01 | 8.23 |
EPS (Basic) |
(12.56) | 32.75 | (29,211.54) | (6.14) | 0.25 | 0.25 |
EPS (Diluted) |
(12.56) | 32.75 | (29,211.54) | — | 0.25 | 0.25 |
Shares (Basic, Weighted) |
0.55 | 0.03 | 0.00 | 8.33 | 32.68 | 32.68 |
Shares (Diluted, Weighted) |
0.55 | 0.03 | 0.00 | — | 32.68 | 32.68 |
EBITDA |
(6.23) | (3.66) | (2.75) | (2.75) | (1.29) | (0.33) |
EBIT |
(6.24) | (3.66) | (2.75) | (2.75) | (2.59) | (0.67) |
Income from Continuous Operations |
(6.94) | 1.01 | (51.16) | (51.16) | — | — |
Income from Discontinued Operations |
— | — | — | 0.00 | — | — |
Consolidated Net Income/Loss |
(6.94) | 1.01 | (51.16) | (51.16) | 8.01 | 8.23 |
EPS (Basic, from Continuous Ops) |
(12.56) | 32.76 | (29,326.25) | (6.14) | — | — |
EPS (Basic, Consolidated) |
(12.56) | 32.76 | (29,326.25) | (6.14) | — | — |
EPS (Diluted, from Cont. Ops) |
(12.56) | 32.76 | (29,326.25) | — | — | — |
Shares (Diluted, Average) |
0.55 | 0.03 | 0.00 | — | — | — |
EPS (Diluted, Consolidated) |
(12.56) | 32.76 | (29,326.25) | — | — | — |
In millions of $ except per-share values · columns are period end dates